

**MINUTES OF TECHNICAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-
BMSIC/DRUGS/24-12/RE-TENDER (RE-TENDER FOR RATE CONTRACT AND SUPPLY OF
QUADRIVALENT HUMAN PAPILLOMA VIRUS (SEROTYPES 6, 11, 16 & 18) VACCINE
(RECOMBINANT) (QHPV) FOR DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 13th December 2024

Venue: BMSICL Conference Hall.

The **Technical Evaluation Committee Meeting for Tender No. BMSIC/DRUGS/24-12/RE-TENDER** was held on **13th December 2024** under the Chairmanship of Dr. Manoj Kumar Choudhary, Director in Chief, Department of Health, GoB. The other committee members present in the meeting were:

1. Sh. Shailesh Kumar, Additional Secretary, Department of Health, GoB.
2. Smt. Kumari Seema, CGM (Supply Chain), BMSICL.
3. Sh. Harendra Ram, GM (Procurement), BMSICL.
4. Sh. Rajesh Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
5. Sh. Sunil Kumar Singh, GM (Logistics), BMSICL.
6. Sh. Navneet Kumar, DGM (Drugs), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/24-12/RE-TENDER.
2. Tender floated date- 26/11/2024.
3. Last date of submission of online bids- 11/12/2024.

3. The Tender has been floated on e-proc2 Portal for the Drug Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) (0.5 ml - 1 dose) Injection.

4. Total two (02) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of original hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

S.N.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s MSD Pharmaceuticals Private Limited	Ok	Received	Ok
2	M/s Serum Institute Of India Private Limited	Ok	Received	Ok

5. The item wise bid received status was as follows:

S.N.	Name of the Drug	Participating Firms	No. of Bids
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s MSD Pharmaceuticals Private Limited M/s Serum Institute Of India Private Limited	2

6. It was therefore unanimously decided to recommend for evaluating the both received bids.

7. After evaluating the bids and close examination of the documents submitted by the firms, the Drug wise technical evaluation findings for each firm were recorded in today's meeting with the help of Drugs Inspectors deputed at BMSICL as follows:

S.N.	Name of the Drug	Participating firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s MSD Pharmaceuticals Private Limited	Qualified	Ok
		M/s Serum Institute Of India Private Limited	Qualified	Ok

8. According to the comparative chart above, a total of two (02) bidders namely, M/s MSD Pharmaceuticals Private Limited & M/s Serum Institute Of India Private Limited were found technically qualified.

9. It was therefore unanimously decided to recommend for opening of the financial bids of the technically qualified bidders on e-proc2 portal.

10. The meeting thus concluded with a vote of thanks.

Sd/-
(Navneet Kumar)
DGM (Drugs), BMSICL, Patna.

Sd/-
(Sunil Kumar Singh)
GM (Logistics), BMSICL.

Sd/-
(Rajesh Kumar)
Administrative Officer-cum-I/C
Procurement, SHSB.

Sd/-
(Harendra Ram)
GM (Procurement), BMSICL, Patna.

Sd/-
(Kumari Seema)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(Shailesh Kumar)
Representative of the Department of Health, GoB.

Sd/-
(Dr. Manoj Kumar Choudhary)
Director in Chief, Health Dept.,
Govt. of Bihar.